- Home
- ASA vs COLL Comparison
ASA vs COLL Comparison
Compare ASA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASA | COLL |
|---|---|---|
| Founded | 1958 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASA | COLL |
|---|---|---|
| Price | $65.63 | $34.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $50.83 |
| AVG Volume (30 Days) | 93.6K | ★ 400.6K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $1.96 | $20.21 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $24.00 | $23.23 |
| 52 Week High | $83.20 | $50.79 |
Technical Indicators
Market Signals| Indicator | ASA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 16.51 |
| Support Level | $63.93 | $34.30 |
| Resistance Level | $73.60 | $36.20 |
| Average True Range (ATR) | 3.71 | 1.59 |
| MACD | -1.40 | -0.70 |
| Stochastic Oscillator | 2.08 | 2.18 |
Price Performance
Historical ComparisonAbout ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.